X4 Pharmaceuticals, Inc.

XFOR

Healthcare|Biotechnology|US

$3.18

+0.11 (+3.58%)

DCF Value

$20.28

Tangible Book / Share

$0.86

Cash / Share

$1.48

Clinical Trials (13)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06056297 A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections	Neutropenia	P3	Recruiting	176	RCT, Double-blind	Mavorixafor, Placebo
NCT03995108 Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome	WHIM Syndrome	P3	Completed	31	RCT, Double-blind	Mavorixafor, Placebo
NCT04154488 A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders	Neutropenia	P1P2	Completed	32	Open-label	Mavorixafor
NCT07902830 A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders	Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia	P2	Not Yet Recruiting	40	Open-label	Mavorixafor
NCT03005327 A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome	WHIM Syndrome	P2	Completed	8	Open-label	X4P-001
NCT02667886 Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma	Clear Cell Renal Cell Carcinoma	P1P2	Completed	74	RCT, Open-label	X4P-001, axitinib
NCT02923531 Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma	Clear Cell Renal Cell Carcinoma	P1P2	Terminated	9	Open-label	X4P-001, Nivolumab
NCT06858696 A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function	Hepatic Insufficiency	P1	Completed	39	Open-label	Mavorixafor
NCT04274738 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4	Waldenstrom's Macroglobulinemia	P1	Completed	16	Open-label	Mavorixafor, Ibrutinib
NCT02680782 A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers	Healthy	P1	Terminated	15	RCT, Open-label	X4P-001
NCT02823405 X4P-001 and Pembrolizumab in Patients With Advanced Melanoma	Melanoma	P1	Completed	16	Open-label	X4P-001, Pembrolizumab
NCT06914869 Drug-Drug Interaction Potential of Mavorixafor	Healthy Participants	P1	Completed	38	RCT, Open-label	Mavorixafor, Carbamazepine, Efavirenz
NCT03087370 A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome	WHIM Syndrome		Withdrawn	—	—	—